ICAM3: A Protein Target for Cancer and Neurodegenerative Diseases

Target Name: ICAM3

NCBI ID: G3385

ICAM3

ICAM3: A Protein Target for Cancer and Neurodegenerative Diseases

ICAM3, also known as soluble intracellular adhesion molecule 3, is a protein that plays a crucial role in cell-cell adhesion and tissue repair. It is a member of the intracellular adhesion molecule (IAM) family, which includes proteins that mediate cell-cell and cell-tissue interactions, including cadherins, jagged, and semaphorins.

ICAM3 is expressed in a wide range of tissues and cells, including epithelial, muscle, and nervous system cells. It is involved in various physiological processes, including cell signaling, migration, and tissue repair.

Due to its involvement in these processes, ICAM3 has been identified as a potential drug target or biomarker. Many studies have suggested that ICAM3 may be a useful target for cancer, neurodegenerative diseases, and other conditions that involve cellular dysfunction.

Currently, there are several ICAM3-based therapies that are in development, including monoclonal antibodies, small interfering RNA (siRNA), and DNA-based therapies. These therapies are designed to target ICAM3 and modulate its function to treat various diseases.

Monoclonal antibodies are a type of therapy that uses antibodies derived from a single cell to selectively bind to a specific protein. In the case of ICAM3, monoclonal antibodies can be used to target ICAM3 and prevent its interaction with other proteins, potentially leading to the inhibition of cellular processes that are necessary for disease progression.

Small interfering RNA (siRNA) is another type of therapy that can be used to target specific genes or proteins. In the case of ICAM3, siRNA can be used to reduce the levels of ICAM3 in cells, potentially leading to the inhibition of cellular processes that are necessary for disease progression.

DNA-based therapies are another type of therapy that uses DNA to treat diseases. In the case of ICAM3, DNA-based therapies can be used to deliver genetic information to cells, potentially leading to the inhibition of cellular processes that are necessary for disease progression.

Conclusion

ICAM3 is a protein that plays a crucial role in cell-cell adhesion and tissue repair. Its involvement in various physiological processes makes it an attractive target for drug development. Currently, several ICAM3-based therapies are in development, including monoclonal antibodies, small interfering RNA (siRNA), and DNA-based therapies. These therapies are designed to target ICAM3 and modulate its function to treat various diseases, including cancer, neurodegenerative diseases, and other conditions that involve cellular dysfunction. Further research is needed to fully understand the potential of ICAM3 as a drug target or biomarker.

Protein Name: Intercellular Adhesion Molecule 3

Functions: ICAM proteins are ligands for the leukocyte adhesion protein LFA-1 (integrin alpha-L/beta-2) (PubMed:1448173). ICAM3 is also a ligand for integrin alpha-D/beta-2. In association with integrin alpha-L/beta-2, contributes to apoptotic neutrophil phagocytosis by macrophages (PubMed:23775590)

The "ICAM3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ICAM3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets